Abstract:
:Dehydroepiandrosterone (DHEA) is an important neurosteroid and has demonstrated efficacy in the improvement of mood and energy. The authors previously reported the efficacy of DHEA augmentation in the management of negative, depressive, and anxiety symptoms of schizophrenia. To characterize further the effects of DHEA administration and to describe any hormonal effects following DHEA augmentation of antipsychotic medication, several hormones were measured (TSH, prolactin, testosterone, insulin, and estradiol) in 27 chronic schizophrenic inpatients receiving DHEA or placebo augmentation for 6 weeks. No significant changes in hormonal blood measures were noted. At the study end point, an association was noted between DHEA-S and TSH levels (P < 0.05) as well as a change in DHEA-S and insulin levels (P < 0.001). A modest nonsignificant decrease in plasma testosterone was observed following DHEA treatment. In subjects receiving DHEA, change in testosterone levels was associated with improvement in anxiety (P < 0.05) and illness severity (P < 0.05). Findings in this preliminary study demonstrate minimal effects on hormonal profiles despite the theoretic possibility that DHEA may elevate various hormones (eg, testosterone) with potential long-term adverse effects. DHEA's clinical efficacy appears to be mediated by other mechanisms, including direct effects on membrane channel-coupled receptors.
journal_name
Clin Neuropharmacoljournal_title
Clinical neuropharmacologyauthors
Strous RD,Maayan R,Kotler M,Weizman Adoi
10.1097/01.wnf.0000188716.25211.58keywords:
subject
Has Abstractpub_date
2005-11-01 00:00:00pages
265-9issue
6eissn
0362-5664issn
1537-162Xpii
00002826-200511000-00003journal_volume
28pub_type
临床试验,杂志文章,随机对照试验abstract::Five of 24 (21%) normal men (volunteers) administered alpha-methyl-para-tyrosine (AMPT), a catecholamine-depleting agent, developed acute dystonic reactions. The finding that catecholamine depletion without receptor blockade is sufficient to cause acute dystonia suggests that a variety of neurotransmitter imbalances m...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-199012000-00009
更新日期:1990-12-01 00:00:00
abstract::Data on a twice-daily dosage schedule with moclobemide in the treatment of depression is limited. In this study, moclobemide 150 mg twice daily (b.i.d.) was compared to two different three-times-daily (t.i.d.) regimens with total daily dosages of 300 and 450 mg, respectively, over a 6-week period. The study was random...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章,多中心研究,随机对照试验
doi:10.1097/00002826-199417001-00002
更新日期:1994-01-01 00:00:00
abstract:OBJECTIVE:Safety and efficacy of botulinum neurotoxin type A preparation NT 201 (Xeomin, Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany) were investigated over 52 weeks in a double-blind, randomized trial with 32 male volunteers. METHODS:Electroneurographic assessments with surface electrodes were performed aft...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/01.WNF.0000240951.18821.50
更新日期:2007-03-01 00:00:00
abstract::We studied the effectiveness of OR-611 and OR-462, two novel inhibitors of the enzyme catechol-O-methyltransferase (COMT), on 3-O-methyldopa (OMD) formation in cynomolgus monkeys following intravenous levodopa administration. OR-611 dose-dependently reduced the area under the OMD concentration-vs-time curve, reduced m...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-199108000-00005
更新日期:1991-08-01 00:00:00
abstract:OBJECTIVES:Aripiprazole and ziprasidone are 2 antipsychotic medications that are relatively devoid of the metabolic adverse effects associated with the second-generation antipsychotics. This study aimed to evaluate the effectiveness of switching to ziprasidone in patients who had insufficient response or intolerance to...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/WNF.0b013e3181d52b85
更新日期:2010-05-01 00:00:00
abstract::A group of four monkeys was rendered parkinsonian with the toxin MPTP. They were then treated chronically with L-DOPA/benserazide 50/12.5 mg/kg given orally daily for 2 months. This dose produced a striking antiparkinsonian effect, but all animals manifested dyskinesia. A series of agents acting primarily on neurotran...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-199310000-00004
更新日期:1993-10-01 00:00:00
abstract::Levodopa is the most effective drug for symptomatic control of Parkinson syndrome (PS). We report a 22-year clinicopathological study of 59 PS cases. Of the entire group, 37 (63%) had an adequate trial on levodopa. Some improvement was noted on that drug in 24 (65%) cases. Improvement was seen in 94% of idiopathic Par...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-199012000-00007
更新日期:1990-12-01 00:00:00
abstract::In this report, we present a patient whose positive symptoms did not improve despite being treated with clozapine monotherapy at a therapeutic dose for 4 months, and whose symptoms began to resolve after aripiprazole long-acting injection adjunction to clozapine. A 22-year-old man was diagnosed as having schizophrenia...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/WNF.0000000000000404
更新日期:2020-09-01 00:00:00
abstract::Myoclonic status epilepticus (MSE) in patients without epilepsy, or de novo MSE, is a rare condition associated with several acute symptomatic etiologies, including drugs and toxins. We describe a 94-year-old woman with Alzheimer dementia and long use of mirtazapine 30 mg/d and alprazolam 1 mg/d who developed MSE appr...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/WNF.0000000000000283
更新日期:2018-07-01 00:00:00
abstract::This study reports the antidepressant efficacy and the safety of amineptine (Survector 100) in a national multicenter open clinical trial (32 hospital centers). Three hundred twenty-four patients with depressive disorders, selected according to DSM-III Diagnostic Criteria and INSERM classification, were treated with a...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章,多中心研究
doi:10.1097/00002826-198912002-00006
更新日期:1989-01-01 00:00:00
abstract::Tolcapone, a central and peripheral catechol O-methyltransferase (COMT) inhibitor, reduces the conversion of L-Dopa into 3-O-methyl-Dopa (3-OMD), thus leading to more stable and sustained L-Dopa plasma levels. This study was designed to evaluate the effects of acute and 6-week tolcapone administration on L-Dopa pharma...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-199901000-00005
更新日期:1999-01-01 00:00:00
abstract:OBJECTIVE:Use of antipsychotic agents in the management of various psychopathologies in Child and Adolescent Psychiatric practice is gradually increasing. This study aimed to evaluate the sociodemographic and clinical features of children and adolescents who applied to an outpatient clinic of child and adolescent psych...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/WNF.0000000000000263
更新日期:2018-01-01 00:00:00
abstract:BACKGROUND:Introduction of old and new generations of antipsychotics leads to significant improvements in the positive symptoms of schizophrenia. However, negative symptoms remain refractory to conventional trials of antipsychotic therapy. Recently, there were several open clinical human trials with curcumin. Curcumin ...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,随机对照试验
doi:10.1097/WNF.0000000000000344
更新日期:2019-07-01 00:00:00
abstract:BACKGROUND:Recent studies indicate that the traditional Japanese herbal medicine yi-gan san (YGS, yokukan-san in Japanese) may be safe and useful for treating behavioral and psychological symptoms in dementia, borderline personality disorder, neuroleptic-induced tardive dyskinesia, and treatment-resistant schizophrenia...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/WNF.0b013e318206785a
更新日期:2011-01-01 00:00:00
abstract::A significant proportion of the interindividual variance in human fatness is attributable to genetic factors. This fact is indicated (inter alia) by studies of identical twins demonstrating that the degree of efficiency with which the body uses excess dietary energy for fat storage is, to a considerable extent, inheri...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,评审
doi:
更新日期:1988-01-01 00:00:00
abstract::trans-Dihydrolisuride, a partial dopamine receptor agonist, was tested for its effects on chorea in a double-blind, crossover clinical study in 10 patients with Huntington's disease. In eight patients, a neurophysiological evaluation was also performed. No reduction in choreic movements or improvement in voluntary mov...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00002826-198910000-00008
更新日期:1989-10-01 00:00:00
abstract:INTRODUCTION:The Restless Legs Syndrome is a common sensorimotor disorder, typically amenable to treatment with dopamine agonist therapy. Dopamine agonists have been associated with emergent impulse control disorders (ICDs) when used in patients with Parkinson disease, and ICDs have now been reported in individuals wit...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/WNF.0b013e31820d6699
更新日期:2011-03-01 00:00:00
abstract:OBJECTIVES:Autism spectrum disorders (ASDs) have core impairments in social communication as well as the presence of repetitive, stereotypic behaviors and restricted interests. Older adolescents and young adults are particularly impacted by these deficits. Preclinical data implicate glutamatergic dysfunction in the pat...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,随机对照试验
doi:10.1097/WNF.0000000000000033
更新日期:2014-05-01 00:00:00
abstract::Despite ongoing dispute over the pathophysiologic basis of migraine, the vasospastic theory of pathogenesis has brought to the forefront a promising class of new antimigraine agents, the Ca2+ channel antagonists. Voltage-dependent Ca2+ channels, integral membrane proteins that permit extracellular Ca2+ to enter cells ...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,评审
doi:10.1097/00002826-198608000-00001
更新日期:1986-01-01 00:00:00
abstract:OBJECTIVE:A multicenter open-label clinical trial was conducted to evaluate the clinical usefulness of topiramate (TPM) as primary or adjunctive therapy for infantile spasms in the postmarketing period in China. METHODS:Thirty-four centers participated in the trial. Patients included in the study had 1 or more seizure...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章,多中心研究
doi:10.1097/WNF.0b013e3180986d43
更新日期:2008-03-01 00:00:00
abstract::Antiepileptic drugs might be effective in the treatment of patients with Posttraumatic Stress Disorder, a condition with unmet pharmacologic needs. We review the literature on the efficacy and tolerability of antiepileptic drugs in Posttraumatic Stress Disorder, both case reports and open studies, as well as controlle...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,评审
doi:10.1097/00002826-200207000-00006
更新日期:2002-07-01 00:00:00
abstract::Studies assessing the effect of transdermal nicotine in Parkinson's disease (PD) have generated mixed results regarding its efficacy to treat motor and cognitive deficits. These studies generally reported good tolerability in nonsmoking PD patients. The authors report the tolerability data of an open trial with transd...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-200309000-00004
更新日期:2003-09-01 00:00:00
abstract::Calcitonin gene-related peptide (CGRP) is a signaling neuropeptide released from activated trigeminal sensory afferents in headache and facial pain disorders. There are a handful of CGRP-targeted therapies currently in phase 3 studies for migraine acute treatment or prevention. Currently, 4 monoclonal antibodies targe...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,评审
doi:10.1097/WNF.0000000000000227
更新日期:2017-07-01 00:00:00
abstract:OBJECTIVE:Neuroleptic malignant syndrome was induced by aripiprazole in a 12 1/2-year-old boy. The patient had a history of reactive airway disease, pervasive developmental disorder, and learning disability. METHOD:The patient was interviewed and examined, and additional history was taken from the medical records. The...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/01.WNF.0000240941.13876.5E
更新日期:2007-01-01 00:00:00
abstract::Chronic posthypoxic myoclonus is characterized by myoclonic jerks that are specifically triggered by action. It is a rare but devastating sequela of hypoxic encephalopathy. We report a 42-year-old female patient with treatment-resistant chronic posthypoxic myoclonus, which improved with administration of the drug agom...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/WNF.0b013e3182613e06
更新日期:2012-09-01 00:00:00
abstract::The mechanism of action of flunarizine (FZ) and cinnarizine (CZ) on the CNS is not fully understood. Computer analysis of saccadic eye movements (SEM) provides a sensitive and objective method for evaluating drug effect on the function of specific brain structures. This study aimed to assess the effect of a single ora...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/00002826-199410000-00003
更新日期:1994-10-01 00:00:00
abstract::Fluctuations in motor performance are the major problems in chronic management of Parkinson's disease. Most of these fluctuations reflect the decline of levodopa availability. As a consequence, levodopa dosage might be increased and the interdose interval progressively shortened. The postsynaptic dopamine receptors at...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:
更新日期:1994-01-01 00:00:00
abstract::We studied the effect of chronic bromocriptine cotherapy on levodopa kinetics in seven patients with Parkinson's disease who were receiving levodopa therapy. Plasma levodopa concentrations were measured after a standard oral levodopa fasting dose over a 5-hour period, on two different sessions, without and with bromoc...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-199212000-00008
更新日期:1992-12-01 00:00:00
abstract::The effects of carbamazepine (CBZ) on spontaneous secretion of prolactin (PRL) and after stimulation with thyrotropin releasing hormone (TRH) were evaluated. Volunteer subjects after acute CBZ administration, and epileptic subjects with complex partial seizures chronically treated with CBZ, were examined. In an epilep...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-198506000-00006
更新日期:1985-01-01 00:00:00
abstract:BACKGROUND:BL-1020, a novel gamma aminobutyric acid (GABA) ester of perphenazine, is a new oral antipsychotic with a strong affinity for dopamine and serotonin receptors. Unlike first- and second-generation antipsychotics, it has agonist activity at GABA(A). OBJECTIVE:This is the first study to examine tolerability an...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,多中心研究
doi:10.1097/WNF.0b013e3181f8d501
更新日期:2010-11-01 00:00:00